Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.

Hoeks M, Yu G, Langemeijer S, Crouch S, de Swart L, Fenaux P, Symeonidis A, Čermák J, Hellström-Lindberg E, Sanz G, Stauder R, Holm MS, Mittelman M, Mądry K, Malcovati L, Tatic A, Almeida AM, Germing U, Savic A, Gredelj Šimec N, Culligan D, Itzykson R, Guerci-Bresler A, Slama B, van de Loosdrecht A, van Marrewijk C, Droste J, Blijlevens N, van Kraaij M, Bowen D, de Witte T, Smith A; EUMDS Registry Participants.

Haematologica. 2019 Jul 5. pii: haematol.2018.212332. doi: 10.3324/haematol.2018.212332. [Epub ahead of print]

2.

Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients.

de Swart L, Crouch S, Hoeks M, Smith A, Langemeijer S, Fenaux P, Symeonidis A, Čermák J, Hellström-Lindberg E, Stauder R, Sanz G, Mittelman M, Holm MS, Malcovati L, Mądry K, Germing U, Tatic A, Savic A, Almeida AM, Gredelj-Šimec N, Guerci-Bresler A, Beyne-Rauzy O, Culligan D, Kotsianidis I, Itzykson R, van Marrewijk C, Blijlevens N, Bowen D, de Witte T; EUMDS Registry Participants.

Haematologica. 2019 Jun 6. pii: haematol.2018.212217. doi: 10.3324/haematol.2018.212217. [Epub ahead of print]

3.

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes.

Itzykson R, Crouch S, Travaglino E, Smith A, Symeonidis A, Hellström-Lindberg E, Sanz G, Čermák J, Stauder R, Elena C, Germing U, Mittelman M, Langemeijer S, Mądry K, Tatic A, Holm MS, Almeida AM, Savic A, Šimec NG, Luño E, Culligan D, Guerci-Bresler A, Malcovati L, van Marrewijk C, Bowen D, de Witte T, Fenaux P; European MDS Registry members.

Blood Adv. 2018 Aug 28;2(16):2079-2089. doi: 10.1182/bloodadvances.2018020495.

4.

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study.

Stauder R, Yu G, Koinig KA, Bagguley T, Fenaux P, Symeonidis A, Sanz G, Cermak J, Mittelman M, Hellström-Lindberg E, Langemeijer S, Holm MS, Mądry K, Malcovati L, Tatic A, Germing U, Savic A, van Marrewijk C, Guerci-Bresler A, Luño E, Droste J, Efficace F, Smith A, Bowen D, de Witte T.

Leukemia. 2018 Jun;32(6):1380-1392. doi: 10.1038/s41375-018-0089-x. Epub 2018 Mar 6.

5.

IFT20 modulates ciliary PDGFRα signaling by regulating the stability of Cbl E3 ubiquitin ligases.

Schmid FM, Schou KB, Vilhelm MJ, Holm MS, Breslin L, Farinelli P, Larsen LA, Andersen JS, Pedersen LB, Christensen ST.

J Cell Biol. 2018 Jan 2;217(1):151-161. doi: 10.1083/jcb.201611050. Epub 2017 Dec 13.

6.

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance.

de Swart L, Smith A, MacKenzie M, Symeonidis A, Neukirchen J, Mikulenková D, Vallespí T, Zini G, Paszkowska-Kowalewska M, Kruger A, Saft L, Fenaux P, Bowen D, Hellström-Lindberg E, Čermák J, Stauder R, Tatic A, Holm MS, Malcovati L, Mądry K, Droste J, Blijlevens N, de Witte T, Germing U.

Ann Hematol. 2017 Jul;96(7):1105-1112. doi: 10.1007/s00277-017-3009-7. Epub 2017 May 20.

7.

Hypermethylation of the VTRNA1-3 Promoter is Associated with Poor Outcome in Lower Risk Myelodysplastic Syndrome Patients.

Helbo AS, Treppendahl M, Aslan D, Dimopoulos K, Nandrup-Bus C, Holm MS, Andersen MK, Liang G, Kristensen LS, Grønbæk K.

Genes (Basel). 2015 Oct 14;6(4):977-90. doi: 10.3390/genes6040977.

8.

Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.

de Swart L, Smith A, Johnston TW, Haase D, Droste J, Fenaux P, Symeonidis A, Sanz G, Hellström-Lindberg E, Cermák J, Germing U, Stauder R, Georgescu O, MacKenzie M, Malcovati L, Holm MS, Almeida AM, Mądry K, Slama B, Guerci-Bresler A, Sanhes L, Beyne-Rauzy O, Luño E, Bowen D, de Witte T.

Br J Haematol. 2015 Aug;170(3):372-83. doi: 10.1111/bjh.13450. Epub 2015 Apr 24.

PMID:
25907546
9.

Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.

Ørskov AD, Treppendahl MB, Skovbo A, Holm MS, Friis LS, Hokland M, Grønbæk K.

Oncotarget. 2015 Apr 20;6(11):9612-26.

10.

Tin-containing silicates: alkali salts improve methyl lactate yield from sugars.

Tolborg S, Sádaba I, Osmundsen CM, Fristrup P, Holm MS, Taarning E.

ChemSusChem. 2015 Feb;8(4):613-7. doi: 10.1002/cssc.201403057. Epub 2015 Jan 21.

PMID:
25605624
11.

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Woll PS, Kjällquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, Erlandsson R, Ngara M, Anderson K, Deng Q, Mead AJ, Stenson L, Giustacchini A, Duarte S, Giannoulatou E, Taylor S, Karimi M, Scharenberg C, Mortera-Blanco T, Macaulay IC, Clark SA, Dybedal I, Josefsen D, Fenaux P, Hokland P, Holm MS, Cazzola M, Malcovati L, Tauro S, Bowen D, Boultwood J, Pellagatti A, Pimanda JE, Unnikrishnan A, Vyas P, Göhring G, Schlegelberger B, Tobiasson M, Kvalheim G, Constantinescu SN, Nerlov C, Nilsson L, Campbell PJ, Sandberg R, Papaemmanuil E, Hellström-Lindberg E, Linnarsson S, Jacobsen SE.

Cancer Cell. 2014 Jun 16;25(6):794-808. doi: 10.1016/j.ccr.2014.03.036. Epub 2014 May 15. Erratum in: Cancer Cell. 2014 Jun 16;25(6):861. Cancer Cell. 2015 Apr 13;27(4):603-5.

12.

Impact of chemotherapy delay on short- and long-term survival in younger and older AML patients: a Danish population-based cohort study.

Ostgard LS, Nørgaard JM, Sengeløv H, Holm MS, Jensen MK, Kallenbach M, Marcher CW, Nielsen OJ, Nørgaard M.

Leukemia. 2014 Sep;28(9):1926-9. doi: 10.1038/leu.2014.157. Epub 2014 May 12. No abstract available.

PMID:
24813919
13.

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial.

Tobiasson M, Dybedahl I, Holm MS, Karimi M, Brandefors L, Garelius H, Grövdal M, Högh-Dufva I, Grønbæk K, Jansson M, Marcher C, Nilsson L, Kittang AO, Porwit A, Saft L, Möllgård L, Hellström-Lindberg E.

Blood Cancer J. 2014 Mar 7;4:e189. doi: 10.1038/bcj.2014.8.

14.

Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.

Toft N, Birgens H, Abrahamsson J, Bernell P, Griškevičius L, Hallböök H, Heyman M, Holm MS, Hulegårdh E, Klausen TW, Marquart HV, Jónsson OG, Nielsen OJ, Quist-Paulsen P, Taskinen M, Vaitkeviciene G, Vettenranta K, Åsberg A, Schmiegelow K.

Eur J Haematol. 2013 May;90(5):404-12. doi: 10.1111/ejh.12097. Epub 2013 Apr 2.

PMID:
23461707
15.

Music during after-death care: a focus group study.

Holm MS, Fålun N, Gjengedal E, Norekvål TM.

Nurs Crit Care. 2012 Nov-Dec;17(6):302-8. doi: 10.1111/j.1478-5153.2012.00525.x. Epub 2012 Aug 5.

PMID:
23061620
16.

Partners' ambivalence towards cardiac arrest and hypothermia treatment: a qualitative study.

Holm MS, Norekvål TM, Fålun N, Gjengedal E.

Nurs Crit Care. 2012 Sep-Oct;17(5):231-8. doi: 10.1111/j.1478-5153.2012.00490.x. Epub 2012 Apr 5.

PMID:
22897809
17.

Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.

Grövdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Holm MS, Tangen JM, Wallvik J, Oberg G, Hokland P, Jacobsen SE, Porwit A, Hellström-Lindberg E.

Br J Haematol. 2010 Aug;150(3):293-302. doi: 10.1111/j.1365-2141.2010.08235.x. Epub 2010 May 20.

PMID:
20497178
18.

Reasons for treating secondary AML as de novo AML.

Ostgård LS, Kjeldsen E, Holm MS, Brown Pde N, Pedersen BB, Bendix K, Johansen P, Kristensen JS, Nørgaard JM.

Eur J Haematol. 2010 Sep;85(3):217-26. doi: 10.1111/j.1600-0609.2010.01464.x. Epub 2010 Apr 29.

PMID:
20456491
19.

Conversion of sugars to lactic acid derivatives using heterogeneous zeotype catalysts.

Holm MS, Saravanamurugan S, Taarning E.

Science. 2010 Apr 30;328(5978):602-5. doi: 10.1126/science.1183990.

20.

High yield of liquid range olefins obtained by converting i-propanol over zeolite H-ZSM-5.

Mentzel UV, Shunmugavel S, Hruby SL, Christensen CH, Holm MS.

J Am Chem Soc. 2009 Nov 25;131(46):17009-13. doi: 10.1021/ja907692t.

PMID:
19877632
21.

Zeolite-catalyzed isomerization of triose sugars.

Taarning E, Saravanamurugan S, Holm MS, Xiong J, West RM, Christensen CH.

ChemSusChem. 2009 Jul 20;2(7):625-7. doi: 10.1002/cssc.200900099. Epub 2009 Jun 27. No abstract available.

PMID:
19562790
22.
23.

Long-term culture of hematopoietic stem cells - validating the stromal component of the CAFC assay.

Olesen G, Tønder H, Holm MS, Hokland P.

Cytotherapy. 2001;3(2):107-16.

PMID:
12028833
24.

Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction.

Stentoft J, Pallisgaard N, Kjeldsen E, Holm MS, Nielsen JL, Hokland P.

Eur J Haematol. 2001 Nov-Dec;67(5-6):302-8.

PMID:
11872078
25.

[Hematopoietic stem cells II. Diagnostic and therapeutic aspects].

Holm MS, Olesen G, Meyer K, Hokland P.

Ugeskr Laeger. 2000 Jan 17;162(3):313-7. Danish.

PMID:
10680464
26.

[Hematopoietic stem cells I. Basal aspects].

Olesen G, Holm MS, Hokland P.

Ugeskr Laeger. 2000 Jan 17;162(3):309-13. Danish.

PMID:
10680463
27.

Natural effector cells in patients with acute myeloid leukemia treated with the immunomodulator Linomide after autologous bone marrow transplantation.

Hokland M, Jørgensen H, Holm MS, Simonsson B, Nilsson B, Bengtsson M, Hokland P.

Eur J Haematol. 1999 Oct;63(4):251-8.

PMID:
10530414
28.

Modulation of T lymphocyte function by the angiogenesis inhibitor AGM-1470.

Berger AE, Dortch KA, Staite ND, Mitchell MA, Evans BR, Holm MS.

Agents Actions. 1993;39 Spec No:C86-8.

PMID:
8273596
29.

1,4-Dihydronaphthoquinones as water-soluble inhibitors of 5-lipoxygenase.

Schaub RG, Yamashita A, Bach MK, White GJ, Toy A, Ghazal NB, Simmons CA, Burdick MD, Brashler JR, Holm MS.

Prostaglandins Leukot Essent Fatty Acids. 1990 Apr;39(4):255-9.

PMID:
2353025
30.

1,4-Dihydronaphthoquinones, hydroindoloquinones, benzofurans, and benzothiophenes as inhibitors of 5-lipoxygenase. Synthesis and structure-activity studies.

Yamashita A, Schaub RG, Bach MK, White GJ, Toy A, Ghazal NB, Burdick MD, Brashler JR, Holm MS.

J Med Chem. 1990 Feb;33(2):775-81.

PMID:
2153828
31.

Ethylnitrosourea treatment increases lectin binding to mouse germ cells.

Holm MS, Berger AE, Swanson K, Ficsor G, Ginsberg LC.

Toxicology. 1987 Nov;46(3):281-94.

PMID:
2445052
32.

Effect of trypsinization on lectin binding to germ cells from ICR and T/t6 mice.

Holm MS, Berger AE, Swanson K, Ginsberg LC.

Biol Reprod. 1987 Sep;37(2):282-7.

PMID:
3676386
33.

Induction of reagin synthesis in the rat with associated and dissociated hemocyanin: effect of antilymphocyte serum.

White GJ, Holm MS.

J Immunol. 1973 Feb;110(2):327-34. No abstract available.

PMID:
4346094
34.

Detection of antibody to denatured DNA in NZB/B1 mice.

Zeleznick LD, Holm MS, Barnett EV.

Proc Soc Exp Biol Med. 1969 Jul;131(3):716-9. No abstract available.

PMID:
4978243

Supplemental Content

Support Center